Luxturna is a gene therapy used to treat inherited retinal dystrophy caused by mutations in both copies of the RPE65 gene. It is designed to restore vision in patients with this rare genetic condition, which can lead to progressive vision loss and blindness. Luxturna works by delivering a normal copy of the RPE65 gene directly into retinal cells through a one-time injection beneath the retina. This enables the cells to produce the functional enzyme necessary for normal vision.<\/p>\n","protected":false},"excerpt":{"rendered":"
Developed by Spark Therapeutics<\/strong>, Luxturna was the first FDA-approved in vivo gene therapy<\/strong> for an inherited disease. It\u00a0is a solution that is used to treat adults and youngsters with loss of vision as a result of obtained retinal dystrophy, an uncommon genetic disorder of the retina (the light delicate membrane at the back of the eye).<\/p>\n","protected":false},"featured_media":163,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[44],"product_cat":[15],"product_tag":[21],"class_list":{"0":"post-161","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_brand-spark-therapeutics","7":"product_cat-uncategorized","8":"product_tag-injectable","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-simple"},"yoast_head":"\n